Nexstim Plc · OMXHEX:NXTMH
Nexstim — H1 2021 Earnings Presentation
8 slides from Nexstim's earnings presentation, Aug 13, 2021
Slide 1: Personalised brain diagnostics and therapy
Nexstim. Personalised brain diagnostics and therapy. Mikko Karvinen| CEO | Nexstim Plc Joonas Juokslahti | CFO | Nexstim Plc Nexstim Plc H1 2021 Financial Results Webinar, 13 August 2021 Nexstim Plc
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as
Slide 3: Nexstim Overview
Nexstim Overview • Nexstim is a Finnish medical technology company operating in the Unique & Proprietary international market, whose neuronavigation TMS technology Technology platform (transcranial magnetic stimulation, TMS) enables individual treatment and diagnosis of patients with severe brain di
Slide 4: Business Summary H1 2021
Nexstim Business Summary H1 2021 • Nexstim’s historically best first half measured by net sales, operating result and result for the review period • Our business has adapted very well to the changes in the operating environment caused by the COVID-19 pandemic ‒ 7 new NBS Systems sold and delivered d
Slide 5: H1 Key Financials
H1 Key Financials Key Financials of the Group Total net sales 3.0M€ +83% 1–6/2021 1–6/2020 • NBS net sales 1.8M€ +96% EUR in thousands Change-% 6 months 6 months • NBT net sales 1.2M€ +67% • System sales 1.6M€ +187% Net Sales 2,958.6 1,614.5 83.3 • Recurring Revenue 1.4M€ +29% Personnel expenses -2,
Slide 6: Key Strategic Objectives for Year 2021
Key Strategic Objectives for Year 2021 1 Focus on achieving profitable revenue growth and strict management of operating expenses Report first results from the two new pilot studies in treating severe depression and/or chronic pain patients with accelerated 2 therapy treatment protocols and seek to
Slide 7: Unique proprietary neuronavigated TMS technology
Nexstim has a unique proprietary neuronavigated TMS technology that delivers best in class mapping and treatment for patients with brain diseases and disorders. We are well positioned to a disruptive shift in depression therapy. With improving economics, driven by record revenue growth and increasin
Slide 8: Thank you!
Thank you! Nexstim Plc Public Presentation 8